Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.
Early use of checkpoint inhibitors after relapsed Hodgkin lymphoma significantly improved survival, identifying a promising first-salvage strategy.
This multi-institutional retrospective study of 116 R/R cHL patients after BV-containing frontline therapy demonstrates excellent OS (97% at 2 years) but suboptimal PFS (61%), with PD-1 blockade in first salvage independently associated with improved post-ASCT PFS. Primary refractory disease after BV-AVD emerges as a critical unmet need with inferior outcomes (2yr PFSHCT 58% vs 86% for relapsed patients).
What the study was
- Study design
- Retrospective multi-institutional cohort study
- Population
- R/R classic Hodgkin lymphoma after frontline BV-containing therapy (City of Hope, Dana-Farber, MSK, Mayo, Utah)
- Sample size
- 116
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Blood Cancer Journal
Why it surfaced
First large multi-institutional dataset for R/R cHL in the BV-AVD era; establishes PD-1 blockade as preferred first salvage; quantifies the primary refractory unmet need post-BV.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.